[go: up one dir, main page]

PE20220581A1 - Composicion farmaceutica para suministro nasal - Google Patents

Composicion farmaceutica para suministro nasal

Info

Publication number
PE20220581A1
PE20220581A1 PE2022000019A PE2022000019A PE20220581A1 PE 20220581 A1 PE20220581 A1 PE 20220581A1 PE 2022000019 A PE2022000019 A PE 2022000019A PE 2022000019 A PE2022000019 A PE 2022000019A PE 20220581 A1 PE20220581 A1 PE 20220581A1
Authority
PE
Peru
Prior art keywords
pharmaceutical composition
composition
nasal
nasal supply
opioid
Prior art date
Application number
PE2022000019A
Other languages
English (en)
Inventor
Jonas Savmarker
Robert Ronn
Andreas Fischer
Original Assignee
Orexo Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orexo Ab filed Critical Orexo Ab
Publication of PE20220581A1 publication Critical patent/PE20220581A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion proporciona una formulacion de composicion farmaceutica solida para administracion nasal que comprende una cantidad farmacologicamente eficaz de un antagonista de opioide seleccionado de naloxona, nalmefeno o naltrexona y un vehiculo farmaceuticamente aceptable que incluyen disacaridos por ejemplo, lactosa o trehalosa; y dextrinas por ejemplo, ciclodextrinas o maltodextrinas. Ademas, pueden comprender un sacarido de alquilo, preferentemente un ester de sacarosa, tal como monolaurato de sacarosa. Dicha composicion se encuentra en forma de polvo producido por secado por pulverizacion, que posteriormente se carga en aplicadores nasales. Dicha composicion puede emplearse en el tratamiento de sobredosis de opioides en sujetos.
PE2022000019A 2019-07-09 2020-05-18 Composicion farmaceutica para suministro nasal PE20220581A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/506,023 US10653690B1 (en) 2019-07-09 2019-07-09 Pharmaceutical composition for nasal delivery
PCT/GB2020/051207 WO2021005325A1 (en) 2019-07-09 2020-05-18 Pharmaceutical composition for nasal delivery

Publications (1)

Publication Number Publication Date
PE20220581A1 true PE20220581A1 (es) 2022-04-20

Family

ID=70736393

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022000019A PE20220581A1 (es) 2019-07-09 2020-05-18 Composicion farmaceutica para suministro nasal

Country Status (15)

Country Link
US (1) US10653690B1 (es)
EP (1) EP3996687A1 (es)
JP (1) JP7753183B2 (es)
KR (1) KR20220034153A (es)
CN (1) CN114096249B (es)
AU (1) AU2020311020A1 (es)
BR (1) BR112022000260A2 (es)
CA (1) CA3145965A1 (es)
CL (1) CL2022000033A1 (es)
CO (1) CO2022000254A2 (es)
IL (1) IL289513A (es)
MX (1) MX2022000368A (es)
PE (1) PE20220581A1 (es)
PH (1) PH12022550009A1 (es)
WO (1) WO2021005325A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114144224B (zh) 2019-03-26 2024-08-09 保科特纳洛克斯恩公司 药物合成物输送器械和方法
US10729687B1 (en) * 2019-07-09 2020-08-04 Orexo Ab Pharmaceutical composition for nasal delivery
FR3098407B1 (fr) * 2019-07-10 2024-12-13 Aptar France Sas Dispositif de distribution nasale de poudre
EP4061336A1 (en) * 2019-11-21 2022-09-28 Torralva Medical Therapeutics LLC Prophylaxis and reversal of stimulant and opioid/opiate overdose and/or toxic exposure
ES2929818T3 (es) 2020-05-18 2022-12-02 Orexo Ab Nueva composición farmacéutica para la administración de fármacos
US11278709B1 (en) 2021-03-12 2022-03-22 Pocket Naloxone Corp. Drug delivery device and methods for using same
US11617716B2 (en) * 2021-06-10 2023-04-04 Belhaven BioPharma Inc. Dry powder formulations of epinephrine and associated methods
US12414916B2 (en) * 2021-06-10 2025-09-16 Belhaven BioPharma Inc. Dry powder formulations of epinephrine and associated methods
CA3239053A1 (en) 2021-11-25 2023-06-01 Jonas Savmarker Pharmaceutical composition comprising biopharmaceutical drug compounds
GB202117016D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical device
IL313016A (en) 2021-11-25 2024-07-01 Orexo Ab A pharmaceutical preparation that includes adrenaline
GB202117007D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical composition
GB202117015D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical composition
GB202117005D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical composition
US12005185B2 (en) 2021-12-17 2024-06-11 Belhaven BioPharma Inc. Medical counter measures including dry powder formulations and associated methods
GB202308123D0 (en) 2023-05-31 2023-07-12 Orexo Ab New copmosition
AU2024280073A1 (en) 2023-05-31 2025-12-11 Orexo Ab Spray-dried compositions comprising adrenergic receptor modulators
CN119326740A (zh) * 2024-12-18 2025-01-21 纳索菲德(上海)制药技术有限公司 一种治疗生物节律失调的鼻脑递释制剂

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5082669A (en) 1989-07-20 1992-01-21 Dainippon Pharmaceutical Co., Ltd. Rapid-releasing oral particle pharmaceutical preparation with unpleasant taste masked
SE8904296D0 (sv) 1989-12-21 1989-12-21 Pharmacia Ab Transdermal system
ATE196427T1 (de) 1993-12-06 2000-10-15 Takeda Chemical Industries Ltd Zusammensetzung mit verbesserter wasserlöslichkeit, enthaltend eine wasserunlösliche oder an wasser schwerunlösliche verbindung
DE19518810A1 (de) 1995-05-26 1996-11-28 Bayer Ag Nasal-Applikator
JP4462761B2 (ja) 1998-03-10 2010-05-12 バルワー エス．アー． 格納容器に格納された液体製品を投与する装置、及び格納容器の充填方法
JP2000178184A (ja) 1998-12-17 2000-06-27 Lion Corp 粒状組成物、錠剤及び粒状組成物の製造方法
GB9908921D0 (en) 1999-04-19 1999-06-16 Britannia Pharmaceuticals Ltd Spray dispenser for opiod antagonists
FR2817847B1 (fr) 2000-12-08 2003-03-28 Tebro Dispositif de distribution de produit fluide ou pulverulent
ITMI20012174A1 (it) * 2001-10-18 2003-04-18 Univ Parma Polvere per somministrazione nasale di farmaci
GB0201367D0 (en) 2002-01-22 2002-03-13 Ml Lab Plc Composition
WO2004054511A2 (en) 2002-12-13 2004-07-01 The Regents Of The University Of California Analgesic combination comprising nalbuphine
KR101170844B1 (ko) * 2003-02-24 2012-08-02 파마슈티칼 프로덕션스, 인크. 경점막 약물 전달 시스템
CN100471497C (zh) 2003-06-25 2009-03-25 中国人民解放军军事医学科学院毒物药物研究所 盐酸纳洛酮鼻粉剂
CN100515511C (zh) 2003-10-09 2009-07-22 株式会社;生命科学活效 鼻腔用粉状药剂施药装置
CN1640402A (zh) 2004-01-02 2005-07-20 广东奇方药业有限公司 一种稳定的纳洛酮粉针剂
IL159729A0 (en) 2004-01-06 2004-06-20 Doron I Friedman Non-aqueous composition for oral delivery of insoluble bioactive agents
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
CN1305474C (zh) * 2004-10-13 2007-03-21 北京国药龙立生物医药新技术有限公司 盐酸纳美芬鼻腔给药制剂
CN1615867A (zh) 2004-10-22 2005-05-18 北京阳光润禾科技有限公司 注射用盐酸纳洛酮冻干粉针制剂
CN1781479B (zh) 2004-12-02 2010-06-30 和记黄埔医药企业有限公司 一种马蔺子素分散体系及其制备方法
NZ556717A (en) 2005-02-10 2010-09-30 Orexo Ab Pharmaceutical compositons useful in the transmucosal administration of drugs using microparticles attached to the surface of larger carrier particles
KR101233235B1 (ko) 2005-08-26 2013-02-15 에스케이케미칼주식회사 초기 용출율이 개선된 프란루카스트 고체분산체의 약제학적조성물 및 그의 제조방법
CN1939358A (zh) 2005-09-30 2007-04-04 江西本草天工科技有限责任公司 肿节风分散片
CN1813739A (zh) 2005-11-25 2006-08-09 王颖 一种注射用盐酸纳美芬冻干粉针制剂
AU2007295178B2 (en) 2006-09-15 2013-04-18 Echo Pharmaceuticals B.V. Granulate containing a pharmaceutically active substance and anemulsifier and method for its manufacture
WO2009040595A1 (en) 2007-09-28 2009-04-02 Wockhardt Research Centre Multi-dose pharmaceutical composition of analgesic for nasal administration
AU2009224418B2 (en) 2008-03-11 2014-12-11 Aska Pharmaceutical Co., Ltd. Solid dispersion, pharmaceutical compositions containing the same, and processes for the production of both
US20090246256A1 (en) 2008-03-27 2009-10-01 Al-Ghananeem Abeer M Compositions and Methods for Transmucosal Delivery of Lofexidine
US8715715B2 (en) 2008-11-03 2014-05-06 Nal Pharmaceuticals Ltd. Dosage form for insertion into the mouth
EP2266563A1 (en) 2009-06-11 2010-12-29 Charité-Universitätsmedizin Berlin (Charité) Use of opioid receptor antagonists for acute treatment of paraphilic arousal states
US8827946B2 (en) 2009-07-31 2014-09-09 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
MX338110B (es) 2009-09-25 2016-04-01 Reddys Lab Ltd Dr Formulaciones que comprenden compuestos de triptano.
CN102068697B (zh) * 2010-12-30 2013-10-16 宜昌人福药业有限责任公司 含有阿片类镇痛剂和阿片受体拮抗剂的药用组合物
AT16553U1 (de) * 2011-05-13 2020-01-15 Euro Celtique Sa Intranasale pharmazeutische Darreichungsformen umfassend Naloxon
CN104470569B (zh) 2012-06-28 2018-04-27 美国政府(由卫生和人类服务部的部长所代表) 用于疫苗和其它治疗试剂的鼻干粉递送系统
FR3007992B1 (fr) 2013-07-05 2018-01-26 Aptar France Sas Dispositif de distribution de produit fluide ou pulverulent.
WO2015095389A1 (en) * 2013-12-18 2015-06-25 Aegis Therapeutics, Llc Compositions for drug administration
CA2875384A1 (en) 2013-12-20 2015-06-20 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
US10085937B2 (en) 2014-03-14 2018-10-02 Adapt Pharma Limited Nasal drug products and methods of their use
US9480644B2 (en) 2014-03-14 2016-11-01 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
US11135155B2 (en) 2014-07-08 2021-10-05 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
WO2016016431A1 (en) 2014-08-01 2016-02-04 Krka, D.D., Novo Mesto Pharmaceutical formulation comprising an opioid agonist and an opioid antagonist prepared by melt granulation using lipid esters
EP3220893B1 (en) 2014-11-14 2023-06-07 Asoltech Srl Composition based on coq10
CN104547220A (zh) 2014-12-30 2015-04-29 陈宏� 一种治疗儿童视觉疲劳的中药组合物及其制剂
US10166197B2 (en) * 2015-02-13 2019-01-01 St. John's University Sugar ester nanoparticle stabilizers
PT3258919T (pt) 2015-02-17 2020-03-26 Lilly Co Eli Formulação em pó nasal para tratamento da hipoglicemia
WO2016161501A1 (en) 2015-04-08 2016-10-13 Ling Chang-Chun Pharmaceutical compositions of polyanionic and non-ionic cyclodextrin-based dendrimers and uses thereof
CN108778423A (zh) * 2016-01-08 2018-11-09 俄亥俄州国家创新基金会 阿片类新生儿脱瘾综合征的治疗和预防
WO2017158439A1 (en) 2016-03-16 2017-09-21 Omegatri As Powders and tablets comprising omega-3 fatty acid derivatives and methods for their production
US20190209464A1 (en) * 2016-06-24 2019-07-11 Opiant Pharmaceuticals, Inc. Compositions, devices and methods for the treatment of alcohol use disorder
EP3493847A4 (en) * 2016-08-03 2020-04-08 REMD Biotherapeutics, Inc. COMBINATION OF GLUCAGON RECEPTOR ANTAGONISTS AND PI3K PATHWAY INHIBITORS FOR THE TREATMENT OF CANCER
AU2017336776A1 (en) 2016-09-28 2019-03-21 Chrono Therapeutics Inc. Transdermal drug delivery device for delivering opioids
WO2018064672A1 (en) 2016-09-30 2018-04-05 Opiant Pharmaceuticals, Inc. Treatment with intranasal naloxone
US20180092839A1 (en) 2016-10-03 2018-04-05 Lance L. Gooberman Medicated spray for treatment of substance abuse, overdose, addiction and impulse control disorders
CA3043028A1 (en) 2016-11-09 2018-05-17 Opiant Pharmaceuticals, Inc. Compositions, devices, and methods for the treatment of opioid-receptor-mediated conditions
JP7312698B2 (ja) 2016-11-18 2023-07-21 オーピアント ファーマシューティカルズ， インコーポレイテッド オピオイド過剰摂取を処置するための組成物および方法
CN106361700A (zh) * 2016-11-25 2017-02-01 威海恒基伟业信息科技发展有限公司 盐酸纳美芬鼻腔给药制剂
US10394770B2 (en) 2016-12-30 2019-08-27 General Electric Company Methods and systems for implementing a data reconciliation framework
WO2018148382A1 (en) 2017-02-10 2018-08-16 Mucodel Pharma Llc Chemically stable compositions of a pharmaceutical active agent in a multi-chambered delivery system for mucosal delivery
CN110996912A (zh) 2017-08-20 2020-04-10 福摩莱克斯医药创新有限公司 用于鼻内递送的干粉组合物
US20180193332A1 (en) 2017-10-09 2018-07-12 Adapt Pharma Operations Limited Low-temperature stable opioid antagonist solutions
CN109953952A (zh) * 2017-12-25 2019-07-02 王旭宁 盐酸纳美芬鼻腔给药制剂

Also Published As

Publication number Publication date
CN114096249A (zh) 2022-02-25
US10653690B1 (en) 2020-05-19
KR20220034153A (ko) 2022-03-17
WO2021005325A1 (en) 2021-01-14
BR112022000260A2 (pt) 2022-03-03
JP7753183B2 (ja) 2025-10-14
CL2022000033A1 (es) 2022-08-19
AU2020311020A1 (en) 2022-03-03
CN114096249B (zh) 2025-02-11
CO2022000254A2 (es) 2022-04-29
IL289513A (en) 2022-03-01
JP2022540227A (ja) 2022-09-14
CA3145965A1 (en) 2021-01-14
PH12022550009A1 (en) 2022-11-21
MX2022000368A (es) 2022-02-03
EP3996687A1 (en) 2022-05-18

Similar Documents

Publication Publication Date Title
PE20220581A1 (es) Composicion farmaceutica para suministro nasal
PH12018501807A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
ME02946B (me) Dimer buprenorfina i njegova upotreba u lecenju gastrointestinalnih poremecaja
NZ732154A (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
FI3435996T3 (fi) Elafibranori käytettäväksi primaarisen biliaarisen kolangiitin hoidossa
MX2011013201A (es) Composiciones para tratar adiccion a drogas y para mejorar comportamiento relacionado a la adiccion.
AR095160A1 (es) Formulaciones farmacéuticas a prueba de alteraciones
GB2545368A (en) Diversion-resistant opioid formulations
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
AR089130A1 (es) FORMAS DE DOSIS FARMACEUTICA QUE COMPRENDEN POLI(e-CAPROLACTONA) Y OXIDO DE POLIETILENO
MX2015012302A (es) Composiciones tópicas y métodos de tratamiento para trastornos de la piel.
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
UA115139C2 (uk) Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту
HK1258704A1 (zh) 藥物組合物和塗料
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
MX2016006667A (es) Derivados de pirrolo-pirrolona y su uso como inhibidores.
MX383077B (es) Composiciones farmaceuticas para la administracion intraocular que comprenden un agente antibacteriano y un agente antiinflamatorio.
AR079654A1 (es) Combinaciones anticancerosas de farmacos a base de artemisinina y otros agentes quimioterapeuticos. uso. composicion farmaceutica. procedimiento de preparacion. metodo de tratamiento.
BR112012029064A2 (pt) formulação farmacêutica na forma de comprimidos de duas camadas compreendendo inibidores da hmg-coa redutase e irbesartan
JOP20200004A1 (ar) تركيبات طويلة المفعول
FI3666258T3 (fi) Menetelmä prader-willin oireyhtymän hoitamiseksi
MX2019001467A (es) Combinación de antagonistas del receptor de glucagon e inhibidores de la trayectoria p13k para el tratamiento del cáncer.
HK1243704A1 (zh) 用於在未接触疟疾的受试者中预防疟疾的他非诺喹的新方案
MX2018010194A (es) Microsferas de buprenorfina de liberacion sostenida (srbm) y metodos de uso de las mismas.
MX2020003697A (es) Formulaciones farmaceuticas que comprenden un agonista del receptor opioide como ingredientes activos, metodos de fabricacion y usos terapeuticos de las mismas.